MX2020007882A - Variantes fc con unión mejorada a fcrn y semivida prolongada. - Google Patents

Variantes fc con unión mejorada a fcrn y semivida prolongada.

Info

Publication number
MX2020007882A
MX2020007882A MX2020007882A MX2020007882A MX2020007882A MX 2020007882 A MX2020007882 A MX 2020007882A MX 2020007882 A MX2020007882 A MX 2020007882A MX 2020007882 A MX2020007882 A MX 2020007882A MX 2020007882 A MX2020007882 A MX 2020007882A
Authority
MX
Mexico
Prior art keywords
binding polypeptides
fcrn
variants
life
enhanced binding
Prior art date
Application number
MX2020007882A
Other languages
English (en)
Inventor
Huawei Qiu
Brian Mackness
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of MX2020007882A publication Critical patent/MX2020007882A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

La presente descripción proporciona polipéptidos de unión (p. ej., anticuerpos e inmunoadhesinas) que comprenden un dominio de Fc modificado. La presente descripción también proporciona ácidos nucleicos que codifican los polipéptidos de unión, vectores de expresión recombinantes, y células huésped para preparar tales polipéptidos de unión. También se proporcionan métodos de uso de los polipéptidos de unión descritos en este documento para tratar la enfermedad.
MX2020007882A 2018-01-26 2019-01-25 Variantes fc con unión mejorada a fcrn y semivida prolongada. MX2020007882A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862622468P 2018-01-26 2018-01-26
PCT/US2019/015204 WO2019147973A1 (en) 2018-01-26 2019-01-25 Fc variants with enhanced binding to fcrn and prolonged half-life

Publications (1)

Publication Number Publication Date
MX2020007882A true MX2020007882A (es) 2020-12-03

Family

ID=65520379

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020007882A MX2020007882A (es) 2018-01-26 2019-01-25 Variantes fc con unión mejorada a fcrn y semivida prolongada.

Country Status (15)

Country Link
US (1) US20190263934A1 (es)
EP (1) EP3743441A1 (es)
JP (2) JP7399880B2 (es)
KR (1) KR20200115568A (es)
CN (1) CN111788221A (es)
AU (1) AU2019212638A1 (es)
BR (1) BR112020015006A2 (es)
CA (1) CA3089602A1 (es)
CO (1) CO2020010269A2 (es)
IL (1) IL276286A (es)
MX (1) MX2020007882A (es)
PH (1) PH12020551134A1 (es)
SG (1) SG11202006905YA (es)
TW (1) TW201940512A (es)
WO (1) WO2019147973A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210024620A1 (en) * 2019-07-25 2021-01-28 Genzyme Corporation Methods of Treating Antibody-Mediated Disorders with FcRn Antagonists
KR20230034954A (ko) * 2020-05-11 2023-03-10 인베티엑스 인코포레이티드 개에서 치료제의 반감기를 증가시키기 위한 조성물 및 사용 방법
CA3193930A1 (en) * 2020-10-29 2022-05-05 Formycon Ag Ace2 fusion proteins and uses thereof
IL308733A (en) 2021-05-27 2024-01-01 Sanofi Sa Fc variant with increased affinity for Fc receptors and improved thermal stability
WO2023021169A1 (en) 2021-08-20 2023-02-23 Intervet International B.V. Antibodies and igg fusion proteins with an extended half-life
WO2023227790A1 (en) 2022-05-27 2023-11-30 Sanofi Natural killer (nk) cell engagers binding to nkp46 and bcma variants with fc-engineering

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837821A (en) 1992-11-04 1998-11-17 City Of Hope Antibody construct
CN1173878A (zh) 1995-10-16 1998-02-18 尤尼利弗公司 双功能或双价抗体片段类似物
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
KR100940380B1 (ko) * 1999-01-15 2010-02-02 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
EP1294904A1 (en) 2000-06-30 2003-03-26 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Heterodimeric fusion proteins
CA2536408A1 (en) 2003-08-22 2005-03-03 Biogen Idec Ma Inc. Improved antibodies having altered effector function and methods for making the same
AU2005285347A1 (en) * 2004-08-19 2006-03-23 Genentech, Inc. Polypeptide variants with altered effector function
BRPI0517837A (pt) 2004-11-12 2008-10-21 Xencor Inc variantes fc com ligação alterada a fcrn
US8802820B2 (en) * 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
ES2523666T3 (es) 2005-05-31 2014-11-28 Board Of Regents, The University Of Texas System Anticuerpos IgG1 con la parte Fc mutada para el aumento de unión al receptor FcRn y usos de los mismos
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
EP2373689A1 (en) * 2008-12-12 2011-10-12 MedImmune, LLC Crystals and structure of a human igg fc variant with enhanced fcrn binding
BR112012015740B1 (pt) * 2009-12-23 2020-09-29 Synimmune Gmbh Anticorpo anti-flt3, seu uso,bem como composição compreendendo o referido anticorpo e molécula de ácido nucleico
WO2011089211A1 (en) * 2010-01-22 2011-07-28 Synimmune Gmbh Anti-cd133 antibodies and methods of using the same
TWI671315B (zh) 2011-03-28 2019-09-11 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
GB201112429D0 (en) * 2011-07-19 2011-08-31 Glaxo Group Ltd Antigen-binding proteins with increased FcRn binding
US20150050269A1 (en) * 2011-09-30 2015-02-19 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
US20140294812A1 (en) * 2013-03-15 2014-10-02 Xencor, Inc. Fc variants that improve fcrn binding and/or increase antibody half-life
CA2904805A1 (en) * 2013-04-29 2014-11-06 F. Hoffmann-La Roche Ag Fc-receptor binding modified asymmetric antibodies and methods of use
SI3215528T1 (sl) * 2014-11-06 2019-11-29 Hoffmann La Roche Variante regije Fc s spremenjeno vezavo FcRn in postopki uporabe
KR20170081253A (ko) 2014-11-10 2017-07-11 에프. 호프만-라 로슈 아게 항-il-1베타 항체 및 이의 사용 방법

Also Published As

Publication number Publication date
PH12020551134A1 (en) 2021-05-31
SG11202006905YA (en) 2020-08-28
IL276286A (en) 2020-09-30
CA3089602A1 (en) 2019-08-01
CO2020010269A2 (es) 2020-12-10
JP2021511830A (ja) 2021-05-13
EP3743441A1 (en) 2020-12-02
BR112020015006A2 (pt) 2020-12-29
AU2019212638A1 (en) 2020-09-17
KR20200115568A (ko) 2020-10-07
JP2024026255A (ja) 2024-02-28
TW201940512A (zh) 2019-10-16
CN111788221A (zh) 2020-10-16
RU2020128177A (ru) 2022-02-28
JP7399880B2 (ja) 2023-12-18
WO2019147973A1 (en) 2019-08-01
US20190263934A1 (en) 2019-08-29

Similar Documents

Publication Publication Date Title
PH12020551134A1 (en) Fc variants with enhanced binding to fcrn and prolonged half-life
MX2018010824A (es) Proteinas de union inducibles y metodos de uso.
PH12018502361A1 (en) Gdf15 fusion proteins and uses thereof
PH12019500122A1 (en) Bispecific antibody-like binding proteins specifically binding to cd3 and cd123
NZ722055A (en) Fcrn antagonists and methods of use
PH12018501280A1 (en) Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
PH12018502213A1 (en) Anti-myostatin antibodies and methods of use
MX2021010354A (es) Conjugados de farmacos de anticuerpos modificados mediante glicoingenieria.
MX2020010235A (es) Vectores de expresion para receptores de engullimiento quimerico, celulas hospederas geneticamente modificadas y usos de los mismos.
MX2019006045A (es) Proteinas triespecificas dirigidas a psma y metodos de uso.
EA202092093A1 (ru) Композиции и способы перепрограммирования tcr с применением слитых белков
PH12018501628A1 (en) Optimized factor viii genes
SG10201808158UA (en) Site-specific glycoengineering of targeting moieties
MX2023001119A (es) Variantes de enzimas y polinucleotidos que las codifican.
AU2019343184A8 (en) Compositions and methods for treating cancer with anti-CD123 immunotherapy
MX2019002903A (es) Receptores de antigeno quimerico que comprenden dominios de tipo iii de fibronectina especificos del bcma y usos de estos.
EA202091198A1 (ru) Полипептиды, содержащие домен d, и их применение
WO2020076977A3 (en) Dll3 single domain antibodies and therapeutic compositions thereof
JOP20210186A1 (ar) مستضدات البروستاتا المستحدثة واستخداماتها
MX2021012336A (es) Receptores de antigeno quimerico anti-dll3 humanizados y usos de los mismos.
NZ629309A (en) Tumour necrosis factor receptor fusion proteins and methods of using the same
NZ724196A (en) Uti fusion proteins
EA201792274A1 (ru) Слитые молекулы вариант iii рецептора эпидермального фактора роста-мезотелин и способы их применения
MX2021011887A (es) Receptores de antigeno quimerico humanizados anti-claudin 18.2 y usos de los mismos.
CR20190513A (es) Proteínas de unión al antígeno anti-jagged1